Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study
Lung Cancer(2021)
摘要
•Interim data from a Phase 3b trial investigating afatinib in a real-world setting.•TKI-naïve patients with EGFRm + NSCLC received afatinib 40 mg orally, once-daily.•Included patients aged ≥65 years, with comorbidities, poor ECOG PS and/or brain mets.•Overall, 99.8 % patients had an AE; grade ≥ 3 AEs were reported in 65.8 % patients.•This real-world study supports findings from RCTs of afatinib in EGFRm + NSCLC.
更多查看译文
关键词
Afatinib,Safety,EGFR mutation,EGFR TKI-naïve,NSCLC
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络